New Delhi: Nutrition company TruNativ on Tuesday said it has raised about USD 30 million (about Rs 283.5 crore) in a Series B funding round led by global healthcare investment firm OrbiMed.
The funding round comprised both a primary capital infusion and a secondary share sale by early investors, according to a company statement.
Following the investment, Sunny Sharma, Senior Managing Director of OrbiMed Asia, and Sumona Chakraborty, Executive Director of OrbiMed, will join TruNativ’s board.
The Mumbai-based startup stated that the newly raised capital will be utilised to expand its nationwide distribution network across direct-to-consumer (D2C), quick commerce, modern trade, pharmacy, and other retail channels. The funds will also be deployed to scale its B2B2C ingredient business, which currently supplies nutrition solutions to several consumer brands in India.
Founded in 2019, TruNativ operates across high-growth nutrition categories, including sugar alternatives, protein, gut health, and beauty wellness.
“For decades, Indian consumers have been underserved: overexposed to sugar, protein deficiency, and dependent on products that promise health but deliver compromise. We built TruNativ to fix that for every household, not just the health-conscious few. OrbiMed’s investment signals that preventive nutrition is no longer a wellness trend – it is a healthcare imperative,” said Pranav Malhotra, Co-Founder and CEO of TruNativ.
